Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440850 · ClinicalTrials.gov registry record · Phase 2
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
A Phase 2 study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT06440850 is a Phase 2 study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 21 participants, roughly in line with the 22-participant average among 3 other Thyroid Gland Papillary Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06440850, a Phase 2 study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Diagnostic Imaging
- DRUG Cobimetinib
- PROCEDURE I-131 Uptake Test
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2026-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06440850
The ClinicalTrials.gov registry entry for NCT06440850 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 22-participant average among 3 other Thyroid Gland Papillary Carcinoma trials with a reported enrollment target. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Gland Papillary Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06440850 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06440850 about?
NCT06440850 is a clinical study titled "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation". This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form ...
What is the current status of trial NCT06440850?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2024-07-15. Estimated completion is 2026-11-22.
What conditions does trial NCT06440850 study?
This clinical trial studies the following conditions: Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma.
What interventions are being tested in trial NCT06440850?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Diagnostic Imaging (PROCEDURE), Cobimetinib (DRUG), I-131 Uptake Test (PROCEDURE).
Who is sponsoring clinical trial NCT06440850?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06440850 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Papillary Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
RECRUITING
Explore more on PlainTrial
Thyroid Gland Papillary Carcinoma
All registered trials for this condition
Thyroid Gland Follicular Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.